Objective To measure the effect on genital warts of the national human papillomavirus vaccination programme in Australia, which started in mid-2007.
Introduction
In 2007 Australia became one of the first countries to implement a nationally funded programme of quadrivalent human papillomavirus vaccination for girls and young women. 1 The ongoing programme offers free vaccination to girls aged 12-13 years in schools. In addition, from 2007 to 2009 two catch-up programmes were implemented-one for 13-18 year old schoolgirls and the other for 18-26 year old women in the community. The quadrivalent vaccine provides protection against human papillomavirus types 6 and 11, which cause genital warts, in addition to the cancer causing types 16 and 18. 2 3 In 2010 the vaccination coverage rates in the school based programme were reported to be 83% for the first dose, 80% for the second dose, and 73% for the third dose in 12-13 year olds, 4 with coverage rates decreasing with increasing age. The lowest rates of 52% for the first dose in 20-26 year olds were observed in the community catch-up programme. 4 5 Few men, or women who were over 26 years of age in 2007, have been vaccinated. 6 We established a sentinel surveillance network to monitor the effect of the vaccine on cases of genital warts seen at sexual health services across Australia. Earlier data from the network showed that two years after the vaccine was introduced the proportion of genital wart diagnoses declined by 59% in vaccine eligible young women aged 12-26 years in 2007 and by 39% in heterosexual men of the same age. 6 No significant decline was observed in older women or men, non-resident young women, or men who have sex with men. 6 In the same two year period, data from the Victorian cervical cytology registry showed a significant decrease in the incidence of high grade cervical abnormalities in girls aged under 18 years. 7 In this study, we describe the ongoing population effect of the quadrivalent human papillomavirus vaccination programme on genital warts in Australian patients five years after the programme was established.
Methods

Surveillance network
Details of the surveillance network methods have been reported elsewhere. 6 In summary, we recruited eight sexual health services dispersed across Australia that were able to provide retrospective data to 2004. Routine data on patients' demographics and behaviour (age, sex, country of birth, and gender of their sexual partners) and clinical diagnosis of genital warts were collated from all sites. In addition, the two largest clinics (Melbourne Sexual Health Centre and Sydney Sexual Health Centre) collected data on self reported human papillomavirus vaccination status of new patients from 2009. This was a dichotomous question (yes/no) and did not record date of vaccination or number of doses of vaccine received.
Data presentation
Australian born patients who attended any of the services for the first time between January 2004 and December 2011 were included in the analysis. Men who reported having sex only with men or with both men and women in the previous 12 months were referred to as men who have sex with men, men who reported having sex with both men and women were referred to as bisexual, men who reported having sex only with men were referred to as homosexual, and men who reported having sex only with women were referred to as heterosexual.
We divided the study period into the pre-vaccination period (from January 2004 to June 2007) and the vaccination period (from July 2007 to December 2011) on the basis of the vaccination programme starting in mid-2007. We calculated the proportion of patients diagnosed as having genital warts by dividing the total number of new diagnoses of warts by the total number of new patients seen. We stratified findings by age group at the time of presentation at the clinic: under 21 year olds-all women in this age group were eligible for the free vaccine at any time in the vaccination period; 21-30 year olds-only a proportion of women in this age group were eligible for the free vaccine; and over 30 year olds-none of the women in this age group were eligible for the free vaccine at any time. We used the same age groups for heterosexual men, although none of these men were eligible for the free vaccine. 
Statistical analysis
We compared the proportion of patients diagnosed as having genital warts in the pre-vaccination and vaccination periods by using rate ratios and determined summary rate ratios along with 95% confidence intervals over the eight year study period. Statistical significance was set at 0.05. We used Stata version 12.1 to do all analyses and fit all models. 
Results
Between
Women under 21 years
We found no significant trend in the proportion of under 21 year old women diagnosed as having genital warts in the pre-vaccination period-8.8% in 2004 and 11.5% in 2007 (P=0.23). In the vaccination period, the proportion declined dramatically by 92.6%, to 0.85% in 2011 with only 13 cases diagnosed (P<0.001) ( fig 1⇓) . The summary rate ratio comparing the vaccination period with the pre-vaccination period in these women was 0.64 (P<0.001) (table 2⇓). 
Women aged 21-30 years
We saw no significant decline in the proportion of 21-30 year old women diagnosed as having genital warts in the pre-vaccination period-12.5% in 2004 and 11.3% in 2007 (P=0.89). In the vaccination period, the proportion declined by 72.6%, to 3.1% in 2011 (P<0.001) ( fig 1⇓) . The summary rate ratio comparing the vaccination period with the pre-vaccination period in this age group was 0.81 (P<0.001) (table 2⇓).
Women over 30 years
We saw no significant trend in the proportion of women aged over 30 years diagnosed as having genital warts either in the pre-vaccination period (from 3.8% in 2004 to 5.6% in 2007; P=0.07) or in the vaccination period (4.4% in 2011; P=0.99) ( fig 1⇓) . The summary rate ratio comparing the vaccination period with the pre-vaccination period in this age group was 1.03 (P=0.48) (table 2⇓).
Heterosexual men under 21 years
We found a significant increasing trend in the proportion of under 21 year old men diagnosed as having genital warts in the pre-vaccination period, with a 68.0% increase from 7.2% in 2004 to 12.1% in 2007 (P<0.01). In the vaccination period, the proportion declined dramatically by 81.8%, to 2.2% in 2011 (P<0.001) ( fig 3⇓) . The summary rate ratio comparing the vaccination period with the pre-vaccination period in these men was 0.72 (P<0.001) (table 2⇓).
Heterosexual men aged 21-30 years
We saw no significant decline in the proportion of 21-30 year old men diagnosed as having genital warts in the pre-vaccination period- 16 
Strengths and limitations of study
The major strength of this study is the inclusion of data from a range of services dispersed across the country, alleviating the concern about possible biases when data are reported from one service or one geographical location. The main limitation of the study is that sexual health services typically target populations that are at higher risk of sexually transmissible infections. In Australia, patients with symptoms are triaged into sexual health services, so these data represent a higher risk section of the population. Thus, a higher proportion of patients seen at sexual health services are expected to have genital warts than in the general population. That being said, the main purpose of this sentinel network was to evaluate trends, and, as shown in our analysis, a sharp decline in diagnoses has occurred in young women and men since the vaccination programme was rolled out in 2007. By contrast, our analyses showed that a significant increase occurred in the proportion of under 21 year old women, under 21 year old heterosexual men, and men who have sex with men who tested positive for chlamydia in the vaccination period , suggesting that the decline in genital warts could not be attributable to the clinics seeing patients at lower risk.
Possible explanations for findings
The greatest decline in the proportion of women diagnosed as having genital warts was seen in the youngest age group (under 21 years), and all these women were eligible for the free quadrivalent human papillomavirus vaccine. A higher proportion of these women would have received the vaccine in school before becoming sexually active. 4 The more modest decline in women aged 21-30 years reflects lower vaccine coverage. 8 The proportion of women aged over 30 years with genital warts was low in the pre-vaccination period, as the peak age for developing genital warts is the late teens and early 20s. 9 No significant drop occurred in the proportion of diagnoses in these older women in the vaccination period, probably because they were ineligible for the free vaccine.
Our data show that genital warts may have disappeared in young women who reported being vaccinated. We were surprised by this finding, as some of these women probably had only one or two doses of vaccine, 8 and false positive diagnoses are always possible. A randomised controlled trial of the quadrivalent human papillomavirus vaccine showed that the vaccine's efficacy as regards clinical disease associated with human papillomavirus 6 and 11 was 100%. 10 Historically, about 90% of cases of genital warts have been assumed to be attributable to human papillomavirus 6 and 11. However, a recent study that analysed lesion tissues reported that 97% of genital warts were attributable to human papillomavirus 6 or 11.
11 Authors of this study point out that most studies use surface swabs to detect human papillomavirus DNA, with the potential that the detection may reflect carriage but not necessarily permissive viral growth. As no genital warts were detected in 2011 in young women vaccinated with quadrivalent human papillomavirus vaccine, it is possible that all cases of genital warts in Australia are attributable to human papillomavirus 6 and 11 (plus possibly human papillomavirus 16 and 18) or that the vaccine is providing cross protection against the other human papillomavirus types that cause warts. It will be interesting to see if this unexpected finding continues into the future and is replicated in other studies.
The decline in genital warts in the two younger age groups of heterosexual men can most likely be attributed to herd immunity, which is the indirect protection that unvaccinated people enjoy as a result of reduced exposure to infection. 12 The decline was greater in men aged under 21 years compared with 21-30 year old men. The decline observed in genital warts in younger women in our study is in line with a published model of transmission of human papillomavirus 16 in Australia, which predicted a 60-100% decline in human papillomavirus 16 in It is also important to appreciate that men were classified into men who have sex with men, heterosexual, homosexual, or bisexual on the basis of the self reported sex of their partners in the previous 12 months. Some misclassification could be present due to the 12 months definition used.
Comparison with other studies
Findings from our study show a larger decline in young women and men than was seen in a recent study from Sweden, which reported an approximately 25% decline in incidence of genital warts in 17-18 year old women and no decline in men from 2006 to 2010. 16 However, the quadrivalent human papillomavirus vaccine was not available free of cost in Sweden during this period; rather, it was commercially available at subsidised rates for girls aged 13-17 years only, leading to low coverage rates (25% among 13-20 year olds for the first dose) compared with the high coverage rates observed in Australia. 16 Similar findings were reported in female patients under 21 years of age presenting to family planning clinics in California, with a 35% decline between 2007 and 2010 (vaccine coverage rate in United States: 49% among 13-17 year olds for first dose); a 19% decline in male patients under 21 years of age was also reported. 17 However, a study from Auckland sexual health service reported relatively larger declines: 63% decline in female patients under 20 years of age (vaccine coverage rates in Auckland: 52% among female patients under 20 years) and a 40% decline in male patients under 20 years of age between 2007 and 2010. 18 
Likely future trends
In 2013, the Australian government started a publically funded programme in which 12-13 year old boys are eligible to receive free quadrivalent human papillomavirus vaccination through school based programmes. A catch-up programme provides free vaccination to 14-15 year old boys for a two year period. 19 20 In addition to preventing genital warts and anal, penile, and oropharyngeal cancer in men, the vaccination programme is expected to increase herd immunity and provide further indirect protection to unvaccinated women. 21 The male quadrivalent human papillomavirus vaccination programme in addition to enhanced coverage rates in the female programme may lead to the control (defined as a reduction of disease incidence or prevalence to a locally acceptable level 22 ), if not elimination, of the target human papillomavirus types in young people in Australia. Future monitoring using data from this network may confirm these expected benefits. Contributors: BD, CKF, and AEG designed and were principal investigators of the study, with assistance from RJG and DGR. HA coordinated the surveillance network, collated data for this study, did the analysis with HW, and wrote the first draft. BD, RJG, THRR and CKF advised on analysis and interpretation. All authors contributed to the final report. BD and HA are the guarantors.
Funding: CSL Biotherapies funded the surveillance network but had no role in study design; data collection, analysis, or interpretation; or writing the report. Only the Kirby Institute had access to the study data, and the authors had sole responsibility of decision for publication.
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: CKF owns shares in CSL Biotherapies; CKF, AEG, DGR, RJG, and BD have received honorariums from CSL Biotherapies; BD and RJG have received honorariums from Sanofi Pasteur MSD; BD, CFK, DGR, AEG, and RJG receive research funding from CSL Biotherapies; BD, CFK, and AEG have received honorariums from Merck; AEG sits on the Australian advisory board for the Gardasil vaccine; TRHR is a site investigator for a Merck human papillomavirus vaccine study.
Ethical approval: Ethical approval for the study was provided by the St Vincent's Hospital's ethics committee (EC00140) and the University of New South Wales ethics committee (EC00142). Further approval was provided by local research ethics committees of all sites.
Data sharing: Study protocol and data dictionary are available from the first author at hali@kirby.unsw.edu.au.
What is already known on this topic
Clinical trials have shown that the quadrivalent human papillomavirus (HPV) vaccine offers up to 100% protection against lesions caused by HPV 6 and 11
Declines in the incidence of genital warts have been documented in several countries, depending on the level of coverage with quadrivalent HPV vaccine About 90% of cases of genital warts are generally thought to be due to HPV 6 and 11
What this study adds
In women, with 83% first dose vaccine coverage, a 93% decline in diagnosis of genital warts was seen by the fifth year of the national quadrivalent HPV vaccination programme in Australia Despite men not being vaccinated, an 82% decline in genital warts occurred in heterosexual men, attributable to herd immunity
No women who reported that they had been vaccinated were diagnosed as having genital warts in the final year of the study Tables   Table 1| Numbers 
